This three day event will discuss aspects of Alzheimer’s Disease development and treatment in an informal academic setting. Topics for discussion include prediction and prevention strategies, vaccine development, drug discovery and care. With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Alzheimer’s Disease.
A late registration fee applied after April 20th 2015
CLICK HERE TO REGISTER
The Deadline for abstract submissions for oral presentation is March 10th 2015
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
- Introduction by the Chair: Dr. Giulio Maria Pasinetti , Icahn School of Medicine at Mount Sinai, NY, USA
- Oral Inflammation, Tooth Loss, Risk Factors, and Association with Progression of Alzheimer’s Disease: Dr Sim K. Singhrao Oral & Dental Sciences Research Group, School of Medicine & Dentistry, University of Central Lancashire, Preston, UK
- Eye-drops of G-CSF Gene Ameliorate Brain Function in Preclincal Neurological Disorder: Dr Philip K. Liu, Massachusetts General Hospital and Harvard Medical School, MA, USA
ORAL PRESENTATIONS
THE BIOLOGICAL UNDERPINNING OF THE TOMM40 POLY-T: EFFECTS OF ALTERING TOM40 PROTEIN EXPRESSION ON MITOCHONDRIAL FUNCTION
William Gottschalk1, Ornit Chiba-Falek1, Michael W. Lutz1, Kahli Zeitlow1, Mirta Mihovilovic1, Allen D. Roses1,2,
1Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA; 2Zinfandel Pharmaceuticals, Chapel Hill, NC, USA
INTERNET-BASED INTERVENTIONS TO REDUCE DEMENTIA CAREGIVER BURDEN: A SYSTEMATIC REVIEW
MI Lapid, S Kung, C Hu, MM Clark, TA Rummans
Presenting and corresponding author:Maria I. Lapid, M.D.Associate Professor of Psychiatry, Program Director, Geriatric Psychiatry, Mayo Clinic Department of Psychiatry and Psychology, Rochester, MN 55905, Phone: (507) 284-4159, Fax: (507) 284-4158
HYPERTENSION MEDIATED AGGRAVATION OF ALZHEIMER’S LIKE PATHOLOGY IN A MOUSE MODEL OF THE DISEASE IS IRRELEVANT TO NEUROINFLAMMATION
D. Cifuentes,* M. Poittevin,* E. Dere, D. Broquères-You, P. Bonnin, J. Benessiano, M. Pocard, J. Mariani, N. Kubis, T. Merkulova-Rainon,* B.I. Lévy*
IVS/INSERM U965, Hôpital Lariboisière, 75475 Paris Cedex 10, France
- Genome Damage/Repair Imbalance as a Common Basis in Neurological Diseases: Dr Muralidhar Hegde, Assistant Professor, Houston Methodist Hospital Research Institute, Houston, Texas, United States
- Is Alzheimer’s disease (AD) infectious?: Professor Frank O. Bastian, MD, LSU Agricultural center, Baton Rouge, LA & Professor of Pathology, Tulane Medical School, New Orleans, LA, US
- Alterations in the trafficking of the Amyloid Precursor Proteins result in endo-lysosomal defects and neuronal decline: Associate Professor Carmela Matrone, Ph.D., Dept. of Biomedicine, Aarhus University, Aarhus, Denmark
ORAL PRESENTATIONS
NOVEL APTAMER TARGETED NEURON PRO SURVIVAL THERAPY IN ALZHEIMER’S DISEASE INTERVENTION
Joan Smith Sonneborn, Ph.D. Emeritus Professor Zoology & Physiology University of Wyoming, Laramie, Wyoming; 82072
BEHAVIORAL AND PSYCHOLOGICAL DISTURBANCES IN DEMENTIA
CA Hermoso, C Pelegrín, FJ Olivera; Luis vives. Zaragoza, Zaragoza. Spain
- The emerging epidemic of dementia in Indigenous Australians: Associate Professor Robert Parker, Top End Mental Health Services, Northern Territory Australia
- Tau promotes synaptic dysfunction in AD: Professor Alain Buisson, Neuroscience, Université Joseph Fourier Grenoble, La Tronche, France
ORAL PRESENTATIONS
THE SPECIAL PHOSPHOLIPIDS PLASMALOGENS, WHICH HAVE BEEN REDUCED IN THE ALZHEIMERS DISEASE PATIENTS, FACILITATE HIPPOCAMPAL-DEPENDENT MEMORY BY MAINTAINING BDNF SIGNALING
Md. Shamim Hossain1, Yuichi Abe2, Masanori Honsho2, Yukio Fujiki2, Kiyotaka Miake3, Hidetaka Fuchuu3, Toshihiko Katafuchi1, 1Department of Integrative Physiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan;
ISORHYNCHOPHYLLINE IMPROVES LEARNING AND MEMORY IMPAIRMENTS INDUCED BY SCOPOLAMINE IN MICE
Z.X. Lin1,*, Y.F. Xian1, S.P. Ip1
1School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.
*Presenting author: Dr. Zhi-Xiu Lin, School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China.
Day 2: Therapeutics and Treatment
08:45 – 09:30 Exhibitions open Registration and Refreshments
- Introduction by the Chair: Modulation of mitochondrial dynamics as an early AD (MCI) therapy: Dr Shirley ShiDu Yan, MD, Distinguished Professor, Chief of Division of Neuroscience and Neurodegenerative diseases, Higuchi Bioscience Center, University of Kansas, Lawrence, USA
- Development of allosteric activators of the Trk receptors for neuroprotection in AD: Dr Nicholas Webster, Ph.D., M.A., Professor of Medicine, Chief, Division of Endocrinology and Metabolism, Associate Director for Shared Resources, Moores Cancer Center, University of California, San Diego, USA
- ACAT1/SOAT1 as a therapeutic target for Alzheimer’s and other related neurodegenerative diseases: Dr Ta Yuan Chang, PhD, Professor, Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
ORAL PRESENTATIONS
NEUTROPHILS INDUCE ALZHEIMER’S DISEASE-LIKE PATHOLOGY AND COGNITIVE DECLINE VIA A MECHANISM DEPENDENT ON LFA-1 INTEGRIN
Elena Zenaro, Enrica Pietronigro, Vittorina Della Bianca, Gennj Piacentino, Ermanna Turano, Bruno Bonetti, Gabriela Constantin; Department of Pathology and Diagnostics, University of Verona, 37134, Verona, Italy
ELECTROPHYSIOLOGICAL MARKERS OF BRAIN CHANGES IN THE CARRIERS OF ALZHEIMER’S RISK VARIANT PICALM
N.V. Ponomareva1, T.V. Andreeva2,3, M.A.Protasova2, L.I.Shagam2, D.D.Malina1, V.F. Fokin1,, A.Yu.Goltsov2 , E.I. Rogaev2,3,4
1Research Center of Neurology RAMS, Moscow, Russia,
- Retro-inverso peptide inhibitors of β-amyloid oligomer formation as a novel treatment for progression of Alzheimer’s disease: Professor David Allsop, Professor of Neuroscience, Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
- Online information about the prevention of Alzheimer’s disease: The good, the bad, and the ugly: Dr. Julie Robillard, University of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
- Loss of Tau function impairs autophagic amyloid clearance: the potential of autophagy-inducing cancer drugs for AD treatment: Assistant Professor Charbel Moussa, MD, PhD, Georgetown University Medical Center, Washington DC, USA
ORAL PRESENTATIONS
FA HAS THE POTENTIAL EFFECT OF TREATING AD BY REGULATING PDE/CAMP/CREB PATHWAY
Hao Huang1,2, Zeng-Chun Ma1, Yu-Guang Wang1, Qian Hong3, Hong-Ling Tan1, Cheng-Rong Xiao1, Qian-De Liang1, Xiang-Lin Tang1, Yue Gao1, College of Life Science and Bioengineering, Beijing University of Technology , Beijing, China; Beijing Institute of Radiation Medicine, Beijing, China
MEMORY GROUPS FOR MILD COGNITIVE IMPAIRMENT: WHAT IS THE BENEFIT?
GJ. KINSELLA, B. ONG, KE. PIKE, E. MULLALY, E. RAND
School of Psychology & Public Health, La Trobe University, Melbourne, Victoria 3086, Australia
RESVERATROL IS SAFE AND WELL-TOLERATED IN INDIVIDUALS WITH MILD-MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE
RS Turner, MD, PhD1, RG Thomas, PhD2, S Craft, PhD3, CH VanDyck, MD4, J Mintzer, MD5, B Reynolds, NP1, JB Brewer, MD, PhD2, RA Rissman, PhD2, R Raman, PhD2, PS Aisen, MD2 for the Alzheimer’s Disease Cooperative Study
(1) Department of Neurology, Georgetown University, Washington, DC, USA, (2) University of California, San Diego, CA, USA, (3) Wake Forest University, Winston-Salem, NC, USA, (4) Yale University, New Haven, CT, USA, (5) Roper St. Francis Healthcare, Charleston, SC, USA
- 5-HT4 receptor agonists and multi-target directed ligands: novel promising agents for prevention of Alzheimer’s disease: Dr Sylvie Claeysen, PhD, HDR, Institut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France
- Nanoliposomes for diagnosis and therapy of Alzheimers -Recent Progress: Professor Sophia G. Antimisiaris, University of Patras, Greece
ORAL PRESENTATIONS
APE1/REF-1 IN ASSOCIATION WITH GINKGOLIDE B AUGMENTS MITOCHONDRIAL OXPHOS AGAINST Aβ(25-35)-INDUCED OXIDATIVE STRESS
Kaur Navrattan1, Dhiman Monisha3, Perez-Polo J. Regino2, and Mantha Anil K.1,2,
1Centre for Biosciences, School of Basic & Applied Sciences, Central University of Punjab, Bathinda, Punjab, India.
MICE DEVELOP B-LYMPHOCYTE DEPENDENT DELAYED COGNITIVE DEFICITS WEEKS AFTER STROKE
K.P. Doyle, M. Solé, R.C. Axtell, T.V. Nguyen, L.N. Quach, G.J. Soler-Llavina, S. Jurado, J. Han, L. Steinman, F.M. Longo, R.C. Malenka and M.S. Buckwalter
Departments of Immunology and Neurology and the Arizona Center on Aging, University of Arizona, PO Box 245221,Tucson, AZ, 85724-5221, USA
- New Cellular and Animal Models for Drug Discovery in Alzheimer’s Disease: Dr Jordan L. Holtzman, University of Minnesota, USA
- Imaging Brain Injury in Diabetes: Assistant Professor Myria Petrou MA MBChB MS, Department of Radiology, Division of Neuroradiology, University of Michigan, Michigan, USA
ORAL PRESENTATIONS
VIDEOPHONE CONVERSATION FOR PSYCHOLOGICAL STABILIZATION OF INDIVIDUALS WITH DEMENTIA
Kiyoshi Yasuda, Noriaki Kuwahara, Kazuhiro Kuwabara, Kazunari Morimoto, & Nobuji Tetsutani
Department of Rehabilitation, Chiba Rosai Hospital, lchihara-shi, 290-0003, Japan
4Aβ1-15-DERIVED MONOCLONAL ANTIBODY REDUCES MORE Aβ BURDENS AND NEUROINFLAMMATION THAN HOMOLOGOUS VACCINE IN APP/PS1 MICE
Yuwei Zhang, Juntao Zou, Junhua Yang and Zhibin Yao* Department of Anatomy and Neurobiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People’s Republic of China
Day 3 Session 1: 09:45 - 12:50 Diagnosis, pathogenesis and prognosis
09:00 – 09:45 Exhibitions open Registration and Refreshments
- Eye movement biomarkers in Alzheimer’s disease: Dr Olivier Coubard, The Neuropsychological Laboratory, Paris, France
- Aberrant cell cycle in Alzheimer’s disease lymphocytes: diagnostic prospects: Professor Urszula Wojda, Head of the Laboratory of Advanced Preclinical Research Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland
ORAL PRESENTATIONS
AUTOMATIC VERSUS EXECUTIVE SEMANTIC MEMORY IMPAIRMENT IN EARLY ALZHEIMER’S DISEASE: A POSSIBLE DIAGNOSTIC TOOL?
C. Carta & A. Venneri
University of Sheffield, Department of Neuroscience, Medical School, Sheffield, S10 2RX, UK
PROGRESSION PATTERN OF BRAIN MINERAL DEPOSITION AS A DIFFERENTIAL INDICATOR OF COGNITIVE DECLINE
L. Clayson1, M.C. Valdés Hernández2, A. Glatz2, J.M. Wardlaw2, J. Starr3
1 College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK
2 Centre for Clinical Brain Sciences, Department of Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK
3Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, UK
NEUROPSYCHIATRIC SYMPOTMS AND DEMENTIA IN PARKINSON’S DISEASE
Authors H. Alzahrani, A. Venneri
University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF
ARE SYMPTOMS OF DEPRESSION AND ANXIETY PREDICTIVE OF THE INCIDENCE OF ALZHEIMER’S DISEASE? FINDINGS FROM THE AUSTRALIAN IMAGING, BIOMARKERS & LIFESTYLE (AIBL) STUDY OF AGING
R Goodsell1, M Albrecht1,2, R Kane1 & J Foster1,3
1School of Psychology & Speech Pathology, Curtin University
2 Maryland Psychiatric Research Center, School of Medicine, University of Maryland
3Neurosciences Unit, Health Department of WA
- Clusterin: a garbage disposal system you can’t do without: Professor Mark R Wilson, School of Biological Sciences, Faculty of Science, Medicine & Health, University of Wollongong, Wollongong, Australia
RED BLOOD CELLS: A NEW PLAYER IN ALZHEIMER’S DISEASE PATHOGENESIS
Francesco Misiti1, Cristiana Carelli-Alinovi2, Bruno Giardina 2,3
1Human, Social and Health Department, University of Cassino and Southern Lazio, V. S.Angelo, Loc. Folcara, 03043 Cassino (FR), Italy
2 Biochemistry and Clinical Biochemistry Institute, Catholic University, School of Medicine, L.go F. Vito n.1, 00168 Rome, Italy;
3CNR- Istituto di Chimica del Riconoscimento Molecolare (ICRM), L.go F. Vito n.1, 00168 Rome, Italy;
BETA-AMYLOID OLIGOMERIZATION IS ASSOCIATED WITH THE GENERATION OF A TYPICAL PEPTIDE MODIFICATION FINGERPRINT WHICH CAN BE SPECIFICALLY TARGETED USING NOVO-EPITOPE ANTIBODIES
A. Schmid, N. Rudinskiy, D. Demurtas, P. Ockl, M. Otto, A. Herrmann, T. Spires-Jones, B. Schneider, C. De Piano & Ch. Fuerer. Proteomics Core Facility, Ecole Polytechnique Fédérale de Lausanne (EPFL), Life Sciences, Lausanne, Switzerland
- Interspecies comparative gene expression profiling revealed impaired insulin production and insulin signaling in Alzheimer’s disease brains: The Hisayama Study: Dr Yusaku Nakabeppu, DVM, D.Sc. Distinguished Professor and Director of Research Center for Nucleotide Pool, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
Day 3 Session 2: 13:50 - 17:00 Management and Care
- Introduction by the Chair: Various phenotypes of Alzheimer’s disease and management strategies: Dr Chuang-Kuo Wu, M.D., Ph.D., FANA, Director, Alzheimer’s Disease Program, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas, USA
- Reduction in Antipsychotic Medication Use Among US Nursing Home Residents: Regulation Revisions and a National Partnership: Professor Jane R. Mort, Pharm.D., Associate Dean for Academic Programs, Professor of Pharmacy Practice, College of Pharmacy, South Dakota State University, USA
- Caregiver burden in dementia in rural Australia: Ms Kaye Ervin, Researcher and Lecturer Rural Health, University of Melbourne, Vic, Australia
ORAL PRESENTATIONS
FUNCTIONAL MEMORY DISORDER- AN IMPORTANT DIFFERENTIAL DIAGNOSIS IN THE MEMORY CLINIC- KEY FEATURES AND REVIEW OF DIAGNOSTIC CRITERIA
Daniel Blackburn, Chris Elsey, Danielle Jones, Sarah Wakefield, Kirtsy Harkness, Annalena Venneri, Paul Drew, Markus Reuber
DESIGN OF MEMORY AIDS AGENT SERVICE BASED LOCATION AND TIME FOR PEOPLE WITH DEMENTIA
SEIKI. TOKUNAGA1, HIROYASU HORIUCHI1, SACHIO. SAIKI1, SHINSUKE. MATSUMOTO1, MASAHIDE. NAKAMURA1. KIYOSHI YASUDA2,
ADDRESS: 1) KOBE UNIVERSITY, KOBE, HYOGO 657-8501 JAPAN
2) CHIBA ROSAI HOSPITAL, ICHIHARA, CHIBA , 290–0003 JAPAN
- Diagnosis of mild cognitive disorders in older adults: the usefulness of evaluation of Activities of Daily Living: Dr Patricia De Vriendt, Vrije Universiteit Brussel & University college Artevelde Ghent, Belgium
- Driving quality care for people with dementia in nursing homes: The impact of large scale inter-professional student clinical placements: Dr Andrew Robinson RN, MNS, PhD, Professor of Aged Care Nursing, School Of Health Sciences., Wicking Dementia Research and Education Centre., University of Tasmania, Hobart, Tasmania, Australia
- Chairman’s Summing Up
Contact
Registration Fee
Registration includes entry to all the event, lunch and all refreshments, networking opportunities and access to exhibitions.
|
REGISTRATION FEE |
LATE REGISTRATION FEE |
|
Standard |
£445 + VAT |
£545 + VAT |
|
Academic |
£295 + VAT |
£395 + VAT |
|
Student |
£195 + VAT |
£295 + VAT |
If you do not want to attend the full three days you can also book single days at the following price
|
REGISTRATION FEE |
LATE REGISTRATION FEE |
Standard |
£195 + VAT |
£275 + VAT |
Academic |
£125 + VAT |
£195 + VAT |
Student |
£95 + VAT |
£145 + VAT |
Discounted Group Bookings
If 3 or more people register together, then you will receive a discount of £20.00 off for each person in the group
These discounts are applied automatically on registration
Bursary applications
Euroscicon will consider all applications for bursaries to cover registration, food and refreshments on the day of an event. We cannot, at this time award money for travel or accommodation. To download an application form see www.euroscicon.com/Bursary.docx
Venue, Accommodation and Travel Details
This event will be held at Cineworld: The O2 Peninsula Square London SE10 0DX United Kingdom
Once inside the O2 building please make your way to Cineworld. A map of the O2 can be found by clicking here
To download the accommodation and travel details please click here
Payment Instructions
Payment must be received prior to the meeting
Credit card
You can pay during your online registration using your credit card. The information taken will be by secure server. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
Paypal
You can either use your Paypal account or click on the no account link to pay directly by credit or debit card
If you wish to pay by cheque,purchase order or bank transfer, please contact sales@euroscicon.com
Abstract and Poster Presentations
All abstracts accepted for oral presentation are also automatically accepted for poster presentation
INSTRUCTIONS
- How to submit your abstract -www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
- Accepted poster instructions - www.lifescienceevents.com/poster-sessions
- Accepted oral presentation instructions - www.lifescienceevents.com/oral-presentations
